CD274 and neoplasm: Given that pembrolizumab relies on an active immune system to exert an anti-tumor effect, the goal of treatment is to increase antigen presentation with the cytotoxic effects of chemotherapy, upregulate PD-L1 expression, and ultimately promote an ICI-mediated anti-tumor effect.